(2) Including ENOVIA Life Sciences Compliance and Quality Management (Q1 2019: €3.3m)
DASSAULT SYSTEMES
ACQUISITIONS AND FOREIGN EXCHANGE IMPACT
(unaudited; in millions of Euros)
In millions of Euros |
Non-IFRS reported |
o/w growth at constant rate and scope |
o/w change of scope impact at current year rate |
o/w FX impact on previous year figures |
||
Q1 2020 |
Q1 2019 |
Change |
||||
Revenue QTD |
1,144.4 |
964.0 |
180.4 |
(9.0) |
175.4 |
13.9 |
DASSAULT SYSTEMES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (IFRS)
(unaudited; in millions of Euros, except per share data and percentages)
In millions of Euros, except per share data and percentages |
IFRS reported |
|
Three months ended |
||
March 31, |
March 31, |
|
2020 |
2019 |
|
Licenses and other software revenue |
172.3 |
213.2 |
Subscription and Support revenue |
841.9 |
642.0 |
Software revenue |
1,014.2 |
855.3 |
Services revenue |
120.5 |
103.6 |
Total Revenue |
€ 1,134.7 |
€ 958.9 |
Cost of software revenue (1) |
(76.5) |
(45.2) |
Cost of services and other revenue |
(119.9) |
(100.6) |
Research and development |
(230.2) |
(180.3) |
Marketing and sales |
(331.3) |
(291.2) |
General and administrative |
(97.4) |
(76.7) |
Amortization of acquired intangible assets and of tangible assets revaluation |
(109.4) |
(50.1) |
Other operating income and expense, net |
(18.9) |
0.9 |
Total Operating Expenses |
(983.7) |
(743.1) |
Operating Income |
€ 151.0 |
€ 215.8 |
Financial revenue and other, net |
(6.5) |
5.2 |
Income before income taxes |
€ 144.5 |
€ 221.0 |
Income tax expense |
(35.3) |
(62.9) |
Net Income |
€ 109.2 |
€ 158.0 |
Non-controlling interest |
3.2 |
2.8 |
Net Income attributable to equity holders of the parent |
€ 112.4 |
€ 160.8 |
Basic net income per share |
0.43 |
0.62 |
Diluted net income per share |
€ 0.43 |
€ 0.62 |
Basic weighted average shares outstanding (in millions) |
259.5 |
258.8 |
Diluted weighted average shares outstanding (in millions) |
263.2 |
260.5 |
(1) Excluding amortization of acquired intangible assets and of tangible assets revaluation
IFRS reported |
Three months ended March 31, 2020 |
|
Change (4) |
Change in constant currencies |
|
Revenue |
18% |
17% |
Revenue by activity |
||
Software revenue |
19% |
17% |
Services revenue |
16% |
15% |
Software Revenue by product line |
||
Industrial Innovation |
(0)% |
(1)% |
Of which CATIA |
0% |
(1)% |
Of which ENOVIA (2) |
(9)% |
(11)% |
Life Sciences (3) |
380% |
368% |
Mainstream Innovation |
5% |
3% |
Of which SOLIDWORKS |
5% |
3% |
Revenue by geography |
||
Americas |
45% |
41% |
Europe |
3% |
3% |
Asia |
10% |
9% |